Das Management akuter psychischer Erkrankungen in der Schwangerschaft

Die Behandlung schwangerer Patientinnen mit akuten psychischen Erkrankungen muss in interdisziplinären Behandlungszentren erfolgen. Notwendige Fachdisziplinen sind Psychiatrie, Geburtshilfe, Neonatologie, Anästhesie und Innere Medizin. Die Risiken einer Psychopharmakotherapie müssen gegen die erheblichen Risiken einer Nichtbehandlung abgewogen werden, wobei für alle Substanzklassen evidenzbasierte Empfehlungen vorliegen.

Schlüsselwörter

Schwangerschaft - Psychose - Depression - Akutpsychiatrie - Psychopharmaka

• Literatur

• 1 Oates M. Perinatal psychiatric disorders: a leading cause of maternal morbidity and mortality. Br Med Bull 2003; 67: 219-229
• 2 Nilsson E, Hultman CM, Cnattingius S. et al. Schizophrenia and offspringʼs risk for adverse pregnancy outcomes and infant death. Br J Psychiatry 2008; 193: 311-315
• 3 Tomson T, Battino D, Perucca E. Teratogenicity of antiepileptic drugs. Curr Opin Neurol 2019; 32: 246-252
• 4 Blotière PO, Raguideau F, Weill A. et al. Risks of 23 specific malformations associated with prenatal exposure to 10 antiepileptic drugs. Neurology 2019; 93: e167-e180
• 5 Jentink J, Dolk H, Loane MA. et al. Intrauterine exposure to carbamazepine and specific congenital malformations: systematic review and case-control study. BMJ 2010; 341: c6581
• 6 Diav-Citrin O, Shechtman S, Tahover E. et al. Pregnancy outcome following in utero exposure to lithium: a prospective, comparative, observational study. Am J Psychiatry 2014; 171: 785-794
• 7 Patorno E, Huybrechts KF, Bateman BT. et al. Lithium use in pregnancy and the risk of cardiac malformations. N Engl J Med 2017; 376: 2245-2254
• 8 Bérard A, Iessa N, Chaabane S. et al. The risk of major cardiac malformations associated with paroxetine use during the first trimester of pregnancy: a systematic review and meta-analysis. Br J Clin Pharmacol 2016; 81: 589-604
• 9 Shyken JM, Babbar S, Babbar S. et al. Benzodiazepines in pregnancy. Clinical Obstet Gynecol 2019; 62: 156-167
• 10 Holland J, Brown R. Neonatal venlafaxine discontinuation syndrome: A mini-review. Eur J Paediatr Neurol 2017; 21: 264-268
• 11 Alwan S, Friedman JM. Safety of selective serotonin reuptake inhibitors in pregnancy. CNS Drugs 2009; 23: 493-509
• 12 Collins KO, Comer JB. Maternal haloperidol therapy associated with dyskinesia in a newborn. Am J Health Syst Pharm 2003; 60: 2253-2255
• 13 Jiang HY, Xu LL, Li YC. et al. Antidepressant use during pregnancy and risk of postpartum hemorrhage: A systematic review and meta-analysis. J Psychiatric Res 2016; 83: 160-167
• 14 Christensen J, Grønborg TK, Sørensen MJ. et al. Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. JAMA 2013; 309: 1696-1703
• 15 Meador KJ, Baker GA, Browning N. et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurology 2013; 12: 244-252
• 16 Tosato S, Albert U, Tomassi S. et al. A systematized review of atypical antipsychotics in pregnant women: Balancing between risks of untreated illness and risks of drug-related adverse effects. J Clin Psychiatry 2017; 78: e477-e489
• 17 Bergemann N, Paulus WE. Psychopharmaka in der Schwangerschaft. Welche Antipsychotika, Tranquilizer und Hypnotika sind geeignet?. Der Nervenarzt 2016; 87: 943-954
• 18 Laux G, Dietmaier O. Psychopharmaka in Schwangerschaft und Stillzeit. In: Laux G, Dietmaier O. Psychopharmaka. Ratgeber für Patienten und Angehörige. 10. Aufl.. Berlin, Heidelberg: Springer; 2018: 69-72
• 19 Huybrechts KF, Hernández-Díaz S, Patorno E. et al. Antipsychotic Use in Pregnancy and the Risk for Congenital Malformations. JAMA Psychiatry 2016; 73: 938-946
• 20 Coshal S, Jones K, Coverdale J. et al. An overview of reviews on the safety of electroconvulsive therapy administered during pregnancy. J Psychiatr Pract 2019; 25